Condition
Cerebral Vasospasm After Subarachnoid Hemorrhage
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Active Not Recruiting1
Unknown1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07305922Recruiting
Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
NCT06881329Active Not Recruiting
Epigenome-wide DNA Methylation Profiling in Aneurysmal Subarachnoid Hemorrhage and Delayed Ischemic Neurologic Deficit
NCT00964548Phase 1CompletedPrimary
Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage
NCT01400360Not ApplicableUnknownPrimary
Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage
Showing all 4 trials